Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
According to our market capitalization data, Eli Lilly (LLY) reached a market cap of $664.56 billion, securing the top spot among global Biotech companies. Johnson & Johnson (JNJ) and AbbVie (ABBV) follow closely behind. The data was last updated on June 02, 2025.
| Rank | Name | Market Cap | Price | MCap(30D) | MCap(1Y) | Country |
|---|---|---|---|---|---|---|
|
1
|
 Eli Lilly
LLY
|
$664.56 B | $740.26 |
-10.0%
|
-10.7%
|
United States
|
|
2
|
 Johnson & Johnson
JNJ
|
$373.40 B | $155.19 |
0.99%
|
8.5%
|
United States
|
|
3
|
 AbbVie
ABBV
|
$329.43 B | $186.50 |
-5.1%
|
20.4%
|
United States
|
|
4
|
 Novo Nordisk A/S
NOVO-B.CO
|
$321.63 B | $72.38 |
-1.2%
|
-49.9%
|
Denmark
|
|
5
|
 Novo Nordisk
NVO
|
$312.36 B | $72.65 |
3.4%
|
-46.2%
|
Denmark
|
|
6
|
 Roche
ROG.SW
|
$258.14 B | $322.18 |
-2.4%
|
18.2%
|
Switzerland
|
|
7
|
 Novartis
NVS
|
$230.14 B | $116.52 |
2.4%
|
16.8%
|
Switzerland
|
|
8
|
 AstraZeneca
AZN
|
$223.01 B | $71.93 |
1.0%
|
-5.9%
|
United Kingdom
|
|
9
|
 Merck
MRK
|
$190.56 B | $75.89 |
-7.2%
|
-38.4%
|
United States
|
|
10
|
 Amgen
AMGN
|
$154.43 B | $287.20 |
3.8%
|
-3.2%
|
United States
|
|
11
|
 Thermo Fisher Scientific
TMO
|
$149.80 B | $396.83 |
-4.6%
|
-29.1%
|
United States
|
|
12
|
 Gilead Sciences
GILD
|
$135.54 B | $108.96 |
7.1%
|
80.1%
|
United States
|
|
13
|
 Pfizer
PFE
|
$133.09 B | $23.41 |
0.29%
|
-14.5%
|
United States
|
|
14
|
 Sanofi
SNY
|
$125.25 B | $49.19 |
-5.6%
|
4.7%
|
France
|
|
15
|
 Vertex Pharmaceuticals
VRTX
|
$114.25 B | $444.92 |
-11.6%
|
-6.0%
|
United States
|
|
16
|
 Bristol-Myers Squibb
BMY
|
$99.18 B | $48.74 |
-3.6%
|
21.3%
|
United States
|
|
17
|
 Chugai Pharmaceutical
4519.T
|
$88.57 B | $53.82 |
-9.4%
|
62.8%
|
Japan
|
|
18
|
 GlaxoSmithKline
GSK
|
$84.48 B | $41.66 |
6.8%
|
4.8%
|
United Kingdom
|
|
19
|
 CSL
CSL.AX
|
$77.44 B | $159.93 |
-3.5%
|
-11.4%
|
Australia
|
|
20
|
 Zoetis
ZTS
|
$75.23 B | $168.98 |
6.7%
|
-1.1%
|
United States
|
|
21
|
 Regeneron Pharmaceuticals
REGN
|
$53.32 B | $493.88 |
-18.7%
|
-50.3%
|
United States
|
|
22
|
 Samsung Biologics
207940.KS
|
$53.22 B | $747.80 |
-1.3%
|
36.4%
|
South Korea
|
|
23
|
 Jiangsu Hengrui Medicine
600276.SS
|
$50.17 B | $7.60 |
7.7%
|
26.0%
|
China
|
|
24
|
 Lonza
LONN.SW
|
$49.93 B | $692.08 |
-3.8%
|
18.6%
|
Switzerland
|
|
25
|
 Daiichi Sankyō
4568.T
|
$49.48 B | $26.57 |
7.3%
|
-28.2%
|
Japan
|
|
26
|
 Takeda Pharmaceutical
TAK
|
$47.11 B | $15.08 |
-2.3%
|
12.5%
|
Japan
|
|
27
|
 Sun Pharmaceutical
SUNPHARMA.NS
|
$47.01 B | $19.59 |
-8.7%
|
18.4%
|
India
|
|
28
|
 Alnylam Pharmaceuticals
ALNY
|
$39.65 B | $304.07 |
11.3%
|
102.4%
|
United States
|
|
29
|
 Argenx
ARGX
|
$35.97 B | $585.59 |
-12.7%
|
51.7%
|
Netherlands
|
|
30
|
 UCB
UCB.VI
|
$34.67 B | $182.45 |
-5.9%
|
25.5%
|
Belgium
|
|
31
|
 DexCom
DXCM
|
$33.54 B | $85.55 |
6.9%
|
-25.5%
|
United States
|
|
32
|
 Novonesis A/S
NSIS-B.CO
|
$33.22 B | $71.32 |
6.6%
|
14.8%
|
Denmark
|
|
33
|
 Novozymes
NZYM.VI
|
$32.97 B | $71.41 |
8.2%
|
27.8%
|
Denmark
|
|
34
|
 Agilent Technologies
A
|
$31.55 B | $111.11 |
3.3%
|
-14.2%
|
United States
|
|
35
|
 Bayer
BAYN.DE
|
$28.08 B | $28.58 |
2.2%
|
-13.2%
|
Germany
|
|
36
|
 BioNTech
BNTX
|
$27.58 B | $114.71 |
-5.2%
|
-6.9%
|
Germany
|
|
37
|
 Otsuka Holdings
4578.T
|
$26.29 B | $49.79 |
-4.0%
|
11.9%
|
Japan
|
|
38
|
 Celltrion
068270.KS
|
$25.42 B | $116.77 |
0.12%
|
-10.1%
|
South Korea
|
|
39
|
 Sandoz Group
SDZ.SW
|
$21.90 B | $50.85 |
13.4%
|
36.7%
|
Switzerland
|
|
40
|
 Teva Pharmaceutical Industries
TEVA
|
$20.79 B | $17.15 |
2.4%
|
-1.2%
|
Israel
|
|
41
|
 LabCorp
LH
|
$20.77 B | $248.09 |
1.2%
|
29.2%
|
United States
|
|
42
|
 Divis Laboratories
DIVISLAB.NS
|
$20.31 B | $76.50 |
8.0%
|
53.8%
|
India
|
|
43
|
 BeiGene
BGNE
|
$20.21 B | $230.86 |
0.00%
|
50.2%
|
China
|
|
44
|
 Hansoh Pharma
3692.HK
|
$19.71 B | $3.32 |
3.9%
|
49.7%
|
China
|
|
45
|
 Biogen
BIIB
|
$19.31 B | $131.77 |
6.6%
|
-43.5%
|
United States
|
|
46
|
 Royalty Pharma
RPRX
|
$18.70 B | $33.26 |
0.30%
|
26.1%
|
United Kingdom
|
|
47
|
 Astellas Pharma
4503.T
|
$17.75 B | $9.92 |
-0.94%
|
-5.8%
|
Japan
|
|
48
|
 bioMérieux
BIM.PA
|
$15.90 B | $134.82 |
-0.08%
|
23.7%
|
France
|
|
49
|
 Baxter
BAX
|
$15.12 B | $29.45 |
0.79%
|
-8.4%
|
United States
|
|
50
|
 United Therapeutics
UTHR
|
$14.62 B | $324.15 |
6.7%
|
15.4%
|
United States
|
|
51
|
 Shionogi
4507.T
|
$14.27 B | $16.78 |
2.4%
|
1.5%
|
Japan
|
|
52
|
 Intra-Cellular Therapies
ITCI
|
$14.05 B | $131.87 |
0.00%
|
92.8%
|
United States
|
|
53
|
 Cipla
CIPLA.NS
|
$13.89 B | $17.20 |
-5.0%
|
1.1%
|
India
|
|
54
|
 Alteogen
196170.KQ
|
$13.53 B | $253.86 |
-2.1%
|
49.5%
|
South Korea
|
|
55
|
 Genmab
GMAB
|
$13.48 B | $21.80 |
-2.8%
|
-27.3%
|
Denmark
|
|
56
|
 Genmab A/S
GMAB.CO
|
$13.36 B | $216.92 |
-3.5%
|
-29.4%
|
|
|
57
|
 Summit Therapeutics
SMMT
|
$13.16 B | $17.73 |
-35.0%
|
106.1%
|
United Kingdom
|
|
58
|
 WuXi Biologics
WXXWY
|
$13.12 B | $6.39 |
1.8%
|
125.0%
|
China
|
|
59
|
 Insmed
INSM
|
$13.01 B | $71.43 |
-3.9%
|
24.7%
|
United States
|
|
60
|
 Illumina
ILMN
|
$12.87 B | $81.32 |
5.2%
|
-18.2%
|
United States
|
|
61
|
 Incyte
INCY
|
$12.68 B | $65.52 |
4.7%
|
10.6%
|
United States
|
|
62
|
 Torrent Pharmaceuticals
TORNTPHARM.NS
|
$12.38 B | $36.59 |
-3.4%
|
19.0%
|
India
|
|
63
|
 Recordati
REC.MI
|
$12.35 B | $60.02 |
0.51%
|
11.8%
|
Italy
|
|
64
|
 Neurocrine Biosciences
NBIX
|
$12.30 B | $124.24 |
12.1%
|
-12.1%
|
United States
|
|
65
|
 Dr. Reddy's
RDY
|
$12.26 B | $14.74 |
6.1%
|
6.0%
|
India
|
|
66
|
 Exelixis
EXEL
|
$11.69 B | $42.87 |
8.0%
|
96.3%
|
United States
|
|
67
|
 Mankind Pharma
MANKIND.NS
|
$11.68 B | $28.25 |
2.2%
|
17.7%
|
India
|
|
68
|
 Catalent
CTLT
|
$11.52 B | $63.48 |
0.00%
|
16.9%
|
United States
|
|
69
|
 Tempus AI
TEM
|
$10.98 B | $63.44 |
2.1%
|
37.1%
|
United States
|
|
70
|
 BioMarin Pharmaceutical
BMRN
|
$10.96 B | $57.16 |
-6.4%
|
-24.0%
|
United States
|
|
71
|
 Zydus Lifesciences
ZYDUSLIFE.NS
|
$10.92 B | $10.86 |
4.2%
|
-7.1%
|
India
|
|
72
|
 Swedish Orphan Biovitrum
SOBI.ST
|
$10.92 B | $31.80 |
-1.1%
|
3.6%
|
Sweden
|
|
73
|
 Exact Sciences
EXAS
|
$10.61 B | $56.26 |
5.5%
|
25.6%
|
United States
|
|
74
|
 Ascendis Pharma
ASND
|
$10.60 B | $175.19 |
-4.6%
|
20.3%
|
Denmark
|
|
75
|
 Revvity
RVTY
|
$10.54 B | $89.44 |
-2.6%
|
-16.7%
|
United States
|
|
76
|
 Lupin Limited
LUPIN.NS
|
$10.48 B | $22.94 |
-6.1%
|
25.7%
|
India
|
|
77
|
 Moderna
MRNA
|
$10.41 B | $26.91 |
-4.6%
|
-82.0%
|
United States
|
|
78
|
 ICON plc
ICLR
|
$10.25 B | $129.05 |
-8.9%
|
-59.7%
|
Ireland
|
|
79
|
 Viatris
VTRS
|
$10.22 B | $8.70 |
3.8%
|
-13.0%
|
United States
|
|
80
|
 Orion Corporation
ORNAV.HE
|
$9.79 B | $68.89 |
5.5%
|
56.0%
|
Finland
|
|
81
|
 Ipsen
IPN.PA
|
$9.75 B | $117.88 |
-0.67%
|
-14.9%
|
France
|
|
82
|
 Qiagen
QGEN
|
$9.72 B | $44.87 |
5.4%
|
2.6%
|
Netherlands
|
|
83
|
 Regencell Bioscience
RGC
|
$9.52 B | $731.71 |
844.2%
|
19006.8%
|
Hong Kong
|
|
84
|
 kyowa Kirin
4151.T
|
$8.61 B | $16.45 |
12.7%
|
-10.9%
|
Japan
|
|
85
|
 Akeso
9926.HK
|
$8.58 B | $9.56 |
-13.7%
|
69.3%
|
China
|
|
86
|
 Medpace
MEDP
|
$8.57 B | $298.11 |
-1.9%
|
-24.3%
|
United States
|
|
87
|
 Blueprint Medicines
BPMC
|
$8.25 B | $127.76 |
-0.48%
|
-3.3%
|
United States
|
|
88
|
 Cerevel Therapeutics
CERE
|
$8.19 B | $44.96 |
0.00%
|
10.7%
|
United States
|
|
89
|
 Eisai
4523.T
|
$7.98 B | $28.27 |
-0.49%
|
-40.0%
|
Japan
|
|
90
|
 Aurobindo Pharma
AUROPHARMA.NS
|
$7.72 B | $13.30 |
-7.6%
|
-4.1%
|
India
|
|
91
|
 Bio-Techne
TECH
|
$7.64 B | $48.72 |
-2.7%
|
-37.6%
|
United States
|
|
92
|
 Abbott India
ABBOTINDIA.NS
|
$7.61 B | $358.05 |
-0.88%
|
17.5%
|
India
|
|
93
|
 Revolution Medicines
RVMD
|
$7.60 B | $40.82 |
-0.99%
|
-1.9%
|
United States
|
|
94
|
 Roivant Sciences
ROIV
|
$7.59 B | $11.17 |
-5.0%
|
1.2%
|
United Kingdom
|
|
95
|
 Corcept Therapeutics
CORT
|
$7.53 B | $70.99 |
4.9%
|
147.8%
|
United States
|
|
96
|
 Verona Pharma
VRNA
|
$7.15 B | $84.10 |
12.4%
|
578.9%
|
United Kingdom
|
|
97
|
 Alkem Laboratories
ALKEM.NS
|
$7.13 B | $59.62 |
0.26%
|
9.2%
|
India
|
|
98
|
 Halozyme Therapeutics
HALO
|
$6.86 B | $55.66 |
-7.5%
|
24.5%
|
United States
|
|
99
|
 BridgeBio Pharma
BBIO
|
$6.73 B | $35.44 |
-10.4%
|
18.2%
|
United States
|
|
100
|
 Jazz Pharmaceuticals
JAZZ
|
$6.71 B | $108.83 |
-8.6%
|
2.2%
|
Ireland
|
|
101
|
 Elanco
ELAN
|
$6.69 B | $13.47 |
39.3%
|
-24.2%
|
United States
|
|
102
|
 Repligen
RGEN
|
$6.68 B | $118.99 |
-16.2%
|
-21.5%
|
United States
|
|
103
|
 Grifols
GRFS
|
$6.66 B | $8.26 |
11.5%
|
13.1%
|
Spain
|
|
104
|
 Charles River Laboratories
CRL
|
$6.65 B | $135.43 |
13.6%
|
-34.8%
|
United States
|
|
105
|
 Hikma Pharmaceuticals
HIK.L
|
$6.38 B | $2896.05 |
6.5%
|
9.3%
|
United Kingdom
|
|
106
|
 ALK-Abelló
ALK-B.CO
|
$6.14 B | $27.73 |
11.9%
|
16.4%
|
Denmark
|
|
107
|
 Madrigal Pharmaceuticals
MDGL
|
$6.07 B | $273.58 |
-10.2%
|
12.1%
|
United States
|
|
108
|
 TG Therapeutics
TGTX
|
$5.68 B | $35.76 |
-6.8%
|
115.0%
|
United States
|
|
109
|
 Yuhan
000100.KS
|
$5.65 B | $75.43 |
-4.9%
|
33.4%
|
South Korea
|
|
110
|
 Telix Pharmaceuticals
TLX.AX
|
$5.63 B | $16.81 |
-12.1%
|
43.9%
|
Australia
|
|
111
|
 Nuvalent
NUVL
|
$5.54 B | $77.19 |
-1.1%
|
8.2%
|
United States
|
|
112
|
 DiaSorin
DIA.MI
|
$5.54 B | $102.76 |
-8.1%
|
-6.9%
|
Italy
|
|
113
|
 Lundbeck
HLUN-B.CO
|
$5.50 B | $5.74 |
13.9%
|
0.60%
|
Denmark
|
|
114
|
 H. Lundbeck A/S
HLUN-A.CO
|
$5.50 B | $4.77 |
7.3%
|
-4.8%
|
Denmark
|
|
115
|
 Glaukos
GKOS
|
$5.42 B | $94.94 |
8.6%
|
-17.5%
|
United States
|
|
116
|
 Ionis Pharmaceuticals
IONS
|
$5.39 B | $33.88 |
-0.42%
|
-13.6%
|
United States
|
|
117
|
 Richter Gedeon
RIG2.F
|
$5.37 B | $29.37 |
-3.3%
|
0.00%
|
|
|
118
|
 Legend Biotech
LEGN
|
$5.34 B | $29.02 |
-13.3%
|
-27.7%
|
United States
|
|
119
|
 Lantheus Holdings
LNTH
|
$5.31 B | $76.71 |
-30.0%
|
-9.0%
|
United States
|
|
120
|
 Axsome Therapeutics
AXSM
|
$5.30 B | $107.62 |
-9.7%
|
40.7%
|
United States
|
|
121
|
 Galenica
GALE.SW
|
$5.26 B | $105.47 |
-2.6%
|
17.8%
|
Switzerland
|
|
122
|
 Alkermes
ALKS
|
$5.13 B | $31.09 |
-2.5%
|
27.2%
|
Ireland
|
|
123
|
 Siegfried Holding
SFZN.SW
|
$5.08 B | $116.00 |
-2.7%
|
9.1%
|
Switzerland
|
|
124
|
 Ono Pharmaceutical
4528.T
|
$5.07 B | $10.78 |
-1.1%
|
-28.8%
|
Japan
|
|
125
|
 Glenmark Pharmaceuticals
GLENMARK.NS
|
$4.95 B | $17.52 |
3.6%
|
30.0%
|
India
|
|
126
|
 Zealand Pharma
ZEAL.CO
|
$4.89 B | $69.21 |
-6.3%
|
-30.6%
|
Denmark
|
|
127
|
 ADMA Biologics
ADMA
|
$4.84 B | $20.27 |
-16.3%
|
102.2%
|
United States
|
|
128
|
 Biocon
BIOCON.NS
|
$4.68 B | $3.91 |
-0.01%
|
15.6%
|
India
|
|
129
|
 Bachem
BANB.SW
|
$4.59 B | $61.16 |
2.3%
|
-32.6%
|
Switzerland
|
|
130
|
 Vaxcyte
PCVX
|
$4.51 B | $34.98 |
-5.2%
|
-55.0%
|
United States
|
|
131
|
 Ipca Laboratories
IPCALAB.NS
|
$4.20 B | $16.56 |
2.6%
|
25.4%
|
India
|
|
132
|
 Hualan Biological Engineering
002007.SZ
|
$4.09 B | $2.24 |
-2.2%
|
-10.2%
|
China
|
|
133
|
 China Resources Pharmaceutical Group
3320.HK
|
$4.05 B | $0.65 |
0.29%
|
-12.0%
|
Hong Kong
|
|
134
|
 Rhythm Pharmaceuticals
RYTM
|
$4.05 B | $63.63 |
-4.8%
|
62.0%
|
United States
|
|
135
|
 Akero Therapeutics
AKRO
|
$4.03 B | $50.61 |
10.5%
|
158.7%
|
United States
|
|
136
|
 Merus
MRUS
|
$4.03 B | $58.21 |
29.3%
|
5.9%
|
Netherlands
|
|
137
|
 Avidity Biosciences
RNA
|
$3.98 B | $33.04 |
-4.0%
|
15.1%
|
United States
|
|
138
|
 PTC Therapeutics
PTCT
|
$3.88 B | $48.99 |
19.4%
|
29.6%
|
United States
|
|
139
|
 Laurus Labs
LAURUSLABS.NS
|
$3.86 B | $7.15 |
-1.2%
|
51.1%
|
India
|
|
140
|
 Santen Pharmaceutical
4536.T
|
$3.83 B | $11.23 |
10.7%
|
0.62%
|
Japan
|
|
141
|
 Soleno Therapeutics
SLNO
|
$3.82 B | $75.74 |
-4.1%
|
72.1%
|
United States
|
|
142
|
 Cytokinetics
CYTK
|
$3.74 B | $31.31 |
-15.4%
|
-37.8%
|
United States
|
|
143
|
 Sarepta Therapeutics
SRPT
|
$3.69 B | $37.53 |
-40.9%
|
-69.7%
|
United States
|
|
144
|
 Perrigo
PRGO
|
$3.67 B | $26.69 |
6.1%
|
-0.26%
|
Ireland
|
|
145
|
 Krystal Biotech
KRYS
|
$3.59 B | $124.24 |
-22.4%
|
-23.3%
|
United States
|
|
146
|
 ACADIA Pharmaceuticals
ACAD
|
$3.58 B | $21.40 |
42.5%
|
41.2%
|
United States
|
|
147
|
 SpringWorks Therapeutics
SWTX
|
$3.52 B | $46.66 |
1.0%
|
18.9%
|
United States
|
|
148
|
 Zai Lab
ZLAB
|
$3.48 B | $31.19 |
-2.6%
|
67.4%
|
China
|
|
149
|
 Genscript Biotech
1548.HK
|
$3.46 B | $1.59 |
11.2%
|
35.6%
|
China
|
|
150
|
 Amneal Pharmaceuticals
AMRX
|
$3.46 B | $7.43 |
-2.9%
|
10.7%
|
United States
|
|
151
|
 Ultragenyx
RARE
|
$3.43 B | $36.26 |
-12.5%
|
-17.3%
|
United States
|
|
152
|
 WuXi AppTec
2359.HK
|
$3.42 B | $8.84 |
9.8%
|
100.1%
|
China
|
|
153
|
 Arcellx
ACLX
|
$3.42 B | $62.12 |
-4.0%
|
15.7%
|
United States
|
|
154
|
 Alvotech
ALVO
|
$3.41 B | $11.30 |
37.3%
|
-18.1%
|
Iceland
|
|
155
|
 Jamjoom Pharmaceuticals Factory Company
4015.SR
|
$3.31 B | $45.73 |
0.59%
|
27.0%
|
Saudi Arabia
|
|
156
|
 Olink Holding
OLK
|
$3.24 B | $26.08 |
0.00%
|
8.5%
|
Sweden
|
|
157
|
 Piramal Pharma
PPLPHARMA.NS
|
$3.19 B | $2.41 |
-2.8%
|
42.6%
|
India
|
|
158
|
 Sinopharm
1099.HK
|
$3.18 B | $2.37 |
1.9%
|
-9.6%
|
China
|
|
159
|
 CRISPR Therapeutics
CRSP
|
$3.18 B | $36.84 |
-3.5%
|
-36.5%
|
Switzerland
|
|
160
|
 Rohto Pharmaceutical
4527.T
|
$3.18 B | $14.07 |
-15.9%
|
-28.1%
|
Japan
|
|
161
|
 Virbac SA
VIRP.PA
|
$3.16 B | $376.83 |
6.6%
|
-5.2%
|
France
|
|
162
|
 Laboratorios Farmaceuticos Rovi
ROVI.MC
|
$3.13 B | $61.27 |
4.0%
|
-37.8%
|
Spain
|
|
163
|
 Protagonist Therapeutics
PTGX
|
$3.11 B | $50.14 |
7.2%
|
59.2%
|
United States
|
|
164
|
 Gland Pharma
GLAND.NS
|
$3.11 B | $18.86 |
11.9%
|
-10.4%
|
India
|
|
165
|
 Catalyst Pharmaceuticals
CPRX
|
$3.04 B | $24.89 |
2.7%
|
54.3%
|
United States
|
|
166
|
 Crinetics Pharmaceuticals
CRNX
|
$2.98 B | $31.82 |
-9.3%
|
-34.1%
|
United States
|
|
167
|
 Viking Therapeutics
VKTX
|
$2.96 B | $26.34 |
-9.1%
|
-57.0%
|
United States
|
|
168
|
 Morphic Therapeutic
MORF
|
$2.86 B | $56.99 |
0.00%
|
85.9%
|
United States
|
|
169
|
 Morphosys
MOR
|
$2.86 B | $18.96 |
0.00%
|
-0.37%
|
Germany
|
|
170
|
 Scholar Rock Holding
SRRK
|
$2.83 B | $29.76 |
-10.9%
|
206.0%
|
United States
|
|
171
|
 Kymera Therapeutics
KYMR
|
$2.82 B | $43.33 |
-11.7%
|
-6.1%
|
United States
|
|
172
|
 KOBAYASHI Pharmaceutical
4967.T
|
$2.74 B | $36.82 |
-2.3%
|
-4.6%
|
Japan
|
|
173
|
 Almirall
ALM.MC
|
$2.68 B | $12.57 |
11.5%
|
16.3%
|
Spain
|
|
174
|
 Immunovant
IMVT
|
$2.63 B | $15.39 |
-2.4%
|
-41.1%
|
United States
|
|
175
|
 MoonLake Immunotherapeutics
MLTX
|
$2.54 B | $40.09 |
-6.9%
|
-7.1%
|
Switzerland
|
|
176
|
 Tecan
TECN.SW
|
$2.48 B | $193.53 |
1.1%
|
-47.9%
|
Switzerland
|
|
177
|
 Lyell Immunopharma
LYEL
|
$2.43 B | $8.22 |
0.46%
|
-83.4%
|
United States
|
|
178
|
 ImmunityBio
IBRX
|
$2.39 B | $2.71 |
26.7%
|
-57.1%
|
United States
|
|
179
|
 Organon
OGN
|
$2.38 B | $9.15 |
6.0%
|
-54.6%
|
United States
|
|
180
|
 Apellis Pharmaceuticals
APLS
|
$2.37 B | $18.87 |
-15.3%
|
-57.8%
|
United States
|
|
181
|
 Longboard Pharmaceuticals
LBPH
|
$2.34 B | $59.98 |
0.00%
|
216.9%
|
United States
|
|
182
|
 HUTCHMED
HCM
|
$2.31 B | $13.50 |
-8.1%
|
-21.7%
|
Hong Kong
|
|
183
|
 Xenon Pharmaceuticals
XENE
|
$2.30 B | $29.97 |
-23.1%
|
-24.9%
|
Canada
|
|
184
|
 Alembic Pharmaceuticals
APLLTD.NS
|
$2.29 B | $11.65 |
12.4%
|
18.4%
|
India
|
|
185
|
 Mirum Pharmaceuticals
MIRM
|
$2.27 B | $45.91 |
0.70%
|
75.4%
|
United States
|
|
186
|
 Arrowhead Pharmaceuticals
ARWR
|
$2.26 B | $16.40 |
14.9%
|
-34.7%
|
United States
|
|
187
|
 BioCryst Pharmaceuticals
BCRX
|
$2.25 B | $10.73 |
-2.5%
|
58.3%
|
United States
|
|
188
|
 Sumitomo Pharma
4506.T
|
$2.23 B | $5.60 |
-10.8%
|
131.8%
|
Japan
|
|
189
|
 Jubilant Pharmova
JUBLPHARMA.NS
|
$2.17 B | $13.68 |
29.3%
|
84.2%
|
India
|
|
190
|
 Bavarian Nordic
BAVA.CO
|
$2.15 B | $27.61 |
9.2%
|
-7.1%
|
Denmark
|
|
191
|
 Apogee Therapeutics
APGE
|
$2.12 B | $36.35 |
-7.0%
|
-20.2%
|
United States
|
|
192
|
 Belite Bio
BLTE
|
$2.12 B | $65.02 |
3.8%
|
32.8%
|
United States
|
|
193
|
 GeneDx Holdings
WGS
|
$2.12 B | $74.13 |
7.6%
|
232.0%
|
United States
|
|
194
|
 NewAmsterdam Pharma Company
NAMS
|
$2.11 B | $18.79 |
-10.5%
|
-4.3%
|
Netherlands
|
|
195
|
 Harmony Biosciences
HRMY
|
$2.04 B | $35.55 |
15.2%
|
15.1%
|
United States
|
|
196
|
 Vericel
VCEL
|
$2.03 B | $40.25 |
5.2%
|
-10.9%
|
United States
|
|
197
|
 CG Oncology
CGON
|
$2.02 B | $26.52 |
-9.1%
|
-28.9%
|
United States
|
|
198
|
 BB Biotech
BION.SW
|
$2.02 B | $36.94 |
-3.0%
|
-23.7%
|
Switzerland
|
|
199
|
 Kiniksa Pharmaceuticals
KNSA
|
$2.01 B | $27.60 |
-1.5%
|
38.8%
|
|
|
200
|
 Vera Therapeutics
VERA
|
$2.01 B | $31.53 |
-25.8%
|
-52.9%
|
United States
|